Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy
|
|
- Jemima Cook
- 6 years ago
- Views:
Transcription
1 european urology 55 (2009) available at journal homepage: Prostate Cancer Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy Philippe Paparel, Angel M. Cronin, Caroline Savage, Peter T. Scardino, James A. Eastham * Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Article info Article history: Accepted July 3, 2008 Published online ahead of print on July 14, 2008 Keywords: Biochemical recurrence Prostate cancer Salvage prostatectomy Abstract Background: Limited data on patterns of recurrence (local or metastatic) after salvage radical prostatectomy (SP) is available. Objective: To examine biochemical, local and metastatic patterns of recurrence in patients undergoing SP for radiation-recurrent prostate cancer. Design, setting, and participants: 146 patients with biopsy-proven local recurrence of prostate cancer after radiation therapy treated with SP were evaluated in a retrospective study at a single institution. Intervention: All patients underwent SP by mainly two surgeons. Measurements: Biochemical recurrence (BCR) after SP was defined as a serum prostate-specific antigen (PSA) level of 0.2 ng/ml or was defined by the initiation of androgen deprivation therapy. All predictors analyzed were determined after radiotherapy, before SP, and included PSA level, clinical stage, biopsy Gleason score, age at SP, and time interval from radiotherapy to SP. Results and limitations: Of the 146 patients treated with SP, 65 developed BCR. The median follow-up period for recurrence-free patients was 3.8 yr; 43 patients (29%) were followed for >5 yr. Overall, the 5-yr recurrence-free probability was 54% (95% CI, 44 63%). Clinical local recurrence occurred in only one patient who also had bone metastases. Overall, there were 16 prostate cancer specific deaths and 19 deaths from other causes. The 5-yr cumulative incidence of death from prostate cancer was 4% (95% CI, 2 11%). Pre-SP serum PSA level and biopsy Gleason score were significantly associated with death due to prostate cancer ( p < and p = 0.002, respectively). This study is retrospective and included carefully selected patients treated over a long period by, mainly, two experienced surgeons. Conclusions: SP provides excellent local cancer control; only one patient in our series experienced a clinical local recurrence. Earlier identification of patients with persistent, viable local cancer despite radiation therapy will appropriately select patients for SP. # 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Division of Urlogy, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, Suite 527, New York, NY 10021, USA. Tel ; Fax: address: easthamj@mskcc.org (J.A. Eastham) /$ see back matter # 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo
2 european urology 55 (2009) Introduction Despite improved methods of delivery (ultrasoundguided brachytherapy, three-dimensional conformal techniques, and intensity-modulated radiation therapy) that have permitted the administration of higher radiation doses with fewer side effects, up to one-third of patients treated with radiation therapy for clinically localized prostate cancer will have evidence of treatment failure [1,2]. The vast majority of patients with recurrence after radiation therapy are identified by an elevated and rising serum prostate-specific antigen (PSA) level (biochemical rather than clinical failure). The challenge for the clinician is to determine whether the PSA-level elevation originates from local persistence (recurrence) of cancer or from distant metastases or both. If the recurrence is local, there remains an opportunity for cure by additional treatment to the primary site. Treatment options for patients with local recurrence of prostate cancer after radiation therapy include expectant management, immediate continuous or intermittent hormonal therapy, or further attempts at cure with additional local therapy including radio-frequency thermal ablation, high-intensity focused ultrasonography (HIFU), cryoablation, brachytherapy, or salvage radical prostatectomy (SP). While additional local therapies are frequently utilized in patients with locally recurrent prostate cancer after radiation therapy, few studies have documented long-term oncologic outcomes for these procedures. Only SP has been shown to eradicate the cancer for 10 yr; the rate of 10 yr of freedom from biochemical recurrence (BCR) after SP alone was 30% to 43%, and 10-yr cancerspecific survival rates of 70% to 77% have been reported [3 5]. While the likelihood of BCR after SP has been documented, little information is available regarding the clinical patterns of recurrence after SP. The purpose of this study is to examine patterns of biochemical, local, and metastatic progression in patients undergoing SP. 2. Methods 2.1. Study population Between June 1984 and September 2006, 149 consecutive patients with biopsy-confirmed, locally recurrent prostate cancer after radiation therapy underwent SP with curative intent. These patients were treated over a long period of time, and over that period of time, practice patterns have changed. Early in this study period most patients underwent a minimum of six-core, transrectal ultrasound-guided prostate biopsies, whereas more recently, patients had biopsies of at least a 12 cores performed to prove local recurrence. Additionally, since 1998, every patient has had preoperative endorectal magnetic resonance imaging (MRI). This study updates an earlier study published in 2004 [6]. Criteria for SP are strict and include the following: a life expectancy >10 yr, the presence of clinically localized prostate cancer determined by biopsy (at the time of radiotherapy and before SP), the absence of significant voiding symptoms or urinary incontinence, a negative evaluation for systemic disease, no evidence of radiation proctitis, and the absence of lymph node involvement (if a standard pelvic lymph node dissection for staging had been performed at the time of radiation). Clinical information was obtained from a prospectively maintained clinical database. Three patients were not followed after SP, leaving 146 (98%) patients available for analysis. This study received institutional review board approval prior to its initiation. Clinical stage was assigned by the treating physician according to the 1992 TNM system. The technique of SP and preoperative patient preparation has been previously described [3]. The SP specimen was analyzed according to the wholemount, step-section technique. Postoperatively, patients were followed up with serum PSA level determination and digital rectal examination every 3 mo for the first 2 yr and annually thereafter. Disease progression after SP was defined as an increase in serum PSA level 0.2 ng/ml (at least two PSA levels had to be abnormal to meet the criterion for failure) or by the initiation of androgen deprivation therapy (ADT) postoperatively. (The focus of our manuscript is the role of SP as monotherapy to cure radiation-recurrent prostate cancer because the use of any adjuvant treatment [primarily ADT] was considered to be a treatment failure.) Patients with disease progression after SP were evaluated for metastatic disease at the discretion of the treating physician. The decision to initiate ADT was made between the patient and the clinician Statistical methods The probability of freedom from biochemical recurrence following SP was estimated using Kaplan-Meier methods. Multivariable Cox proportional-hazards regression was used to evaluate predictors of BCR following SP. All predictors analyzed were determined postradiotherapy and pre-sp and included the following: PSA, clinical stage, biopsy Gleason score, age at SP, and interval from radiotherapy to SP. As an exploratory analysis, we assessed the association of PSA doubling time (PSA DT) with recurrence using univariate analyses in the subset of 100 patients with a calculable PSA DT. The cumulative incidence of death due to prostate cancer following SP was estimated by adjusting for the competing risk of death due to other causes [7]. A proportional-hazards regression model, adjusting for the competing risk, was used to univariately evaluate predictors of death due to prostate cancer [8]. Multivariable analyses were not conducted because of the limited number of events. Statistical analyses were conducted using Stata 9.0 (Stata Corp, College Station, TX, USA) and R (R Foundation for Statistical Computing, Wien, Austria) with the cmprsk package.
3 406 european urology 55 (2009) Results Patient characteristics are summarized in Table 1. Sixty-five patients had a recurrence after SP (60 patients met the definition of BCR, while 5 patients received hormonal therapy prior to BCR following SP). The median follow-up period for patients without BCR was 3.8 yr; 43 patients (29%) were followed-up for >5 yr. The 5-yr recurrence-free probability was 54% (95% CI, 44 63%; Fig. 1). On multivariable analysis, post radiation therapy (RT), pre-sp biopsy Gleason score was significantly associated with recurrence ( p = 0.047; Table 2). In particular, the hazard ratio for recurrence among patients with biopsy Gleason score 8 in relation to biopsy Gleason grade 6 was 2.71 (95% CI, ). The 5-yr recurrence-free probability was 54% (95% CI, 36 69%) for biopsy Gleason score 6 and 57% (95% CI, 43 70%) for biopsy Gleason score 7 compared to only 35% (95% CI, 11 61%) for biopsy Gleason score 8 (Fig. 2). Pre-SP PSA (hazard ratio [HR]: 1.02; 95% CI, ; p = 0.10) and age at SP (HR: 1.04; 95% CI, ; p = 0.15) both showed marginal associations with recurrence. On exploratory univariate analysis, PSA DT between RT and SP Table 1 Summary data on 146 patients undergoing salvage prostatectomy (SP) for radiation therapy (RT) recurrent prostate cancer. Data are given as median (interquartile range) or frequency (percentage) No. of patients 146 Age at SP (yr) 65 (61 69) Pre-SP PSA (ng/ml; n = 130) 5.1 ( ) PSA doubling time between RT and SP 9.9 ( ) (mo; n = 100) Interval from RT to SP (yr; n = 139) 4.6 ( ) Post-RT clinical stage (n = 137) <T2b 58 (42%) T2b 79 (58%) Fig. 1 Kaplan-Meier probability of freedom from recurrence following salvage prostatectomy. was not significantly associated with recurrence (HR: 0.99 per month; 95% CI, ; p = 0.6). Eighteen (13%) of the 136 patients who underwent a pelvic lymph node dissection at the time of SP were found to have nodal metastases. While the majority of these patients developed BCR, four remained free of disease without hormonal therapy at 1 yr, 2 yr, 7 yr, and 20 yr after SP, respectively. Of the 65 patients who had recurrences, 41 received hormone therapy after SP (5 patients received hormone therapy before the recurrence, and 36 patients received it after the recurrence). Twenty-nine patients progressed to hormonerefractory disease, that is, they developed a documented rise in PSA level despite hormone therapy. Twenty-four of 65 patients who had recurrences subsequently developed radiographic evidence of metastasis. Only one patient developed a clinically detectable local recurrence during the follow-up period. No patient developed upper-tract obstruction. Post-RT biopsy Gleason score 6 49 (34%) 7 61 (42%) 8 16 (11%) Not graded due to treatment effect 8 (5%) Unknown 12 (8%) Post-SP pathology Gleason score 6 15 (10%) 7 83 (57%) 8 29 (20%) Not graded due to treatment effect 2 (1%) Unknown 17 (12%) Extraprostatic extension (n = 143) 80 (56%) Seminal vesical invasion (n = 142) 54 (38%) Lymph node involvement (n = 136) 18 (13%) Positive surgical margins 24 (16%) PSA, prostate-specific antigen. Fig. 2 Kaplan-Meier probability of freedom from recurrence following salvage prostatectomy by biopsy Gleason score.
4 european urology 55 (2009) Table 2 Multivariable Cox proportional-hazards regression to evaluate predictors of biochemical recurrence following salvage prostatectomy (SP) for radiation therapy (RT) recurrent prostate cancer (106 patients with complete data for all predictors were included in the analysis). Predictor Hazard ratio 95% CI p value Pre-SP PSA (ng/ml) Post-RT clinical stage 0.4 <T2b Reference Reference T2b Post-RT biopsy Gleason score Reference Reference Age at SP (yr) Interval from RT to SP (yr) PSA, prostate-specific antigen. Table 3 Univariate proportional-hazards regression to evaluate predictors of death from prostate cancer following salvage prostatectomy (SP), adjusting for the competing risk of death from other causes Predictor Hazard ratio 95% CI p value Pre-SP PSA (ng/ml) < Post-RT clinical stage 0.4 <T2b Reference Reference T2b Post-RT biopsy Gleason grade Reference Reference Age at SP (yr) Interval from RT to SP (yr) RT, radiation therapy; PSA, prostate-specific antigen. In total, there were 35 patient deaths: 16 patients died of prostate cancer, and 19 patients died of other causes. The median follow-up period for survivors was 4.6 yr. The 5-yr cumulative incidence of death due to prostate cancer was 4% (95% CI: 2%, 11%; Fig. 3). Predictors of death from prostate cancer were similar to those obtained for the outcome of biochemical recurrence (Table 3): with univariate analysis, PSA and biopsy Gleason score before SP were significantly associated with death due to prostate cancer ( p < and p = 0.002, respectively). Four of 49 patients with biopsy Gleason score 6 died of prostate cancer, 4 of 61 patients with biopsy Gleason score 7 died of prostate cancer, and 5 of 16 patients with biopsy Gleason score 8 died of prostate cancer. Only 1 of 49 patients and 2 of 55 patients with PSA levels measured before SP of <4 and 4 10, respectively, subsequently died of prostate cancer; 6 of 26 patients with PSA 10 died of prostate cancer. In the remaining seven patients who died of prostate cancer, the pre-sp serum PSA level was Fig. 3 Cumulative incidence of death from prostate cancer following salvage prostatectomy.
5 408 european urology 55 (2009) unknown. PSA DT between RT and SP was not significantly associated with disease-specific death (HR: 0.99/mo; 95% CI, ; p = 0.2). 4. Discussion The primary goal of any salvage local therapy for radiation-recurrent prostate cancer is to provide a durable cure; the prevention of symptomatic local and systemic progression is a secondary objective. As such, the oncologic efficacy of any treatment is judged by the ability of that treatment to accomplish these goals. It is difficult to assess the outcomes of most currently available salvage therapies because of a lack of long-term outcome data and/or the small sample size reported in published series [9 16]. While each of these salvage therapies (HIFU, brachytherapy, cryotherapy, SP) can be safely delivered, information regarding the benefit they provide in terms of cancer control is limited. Gelet et al reported their experience with salvage HIFU [16]. A total of 71 patients were treated with a mean follow-up period of only 14.8 mo. Efficacy was assessed by posttreatment biopsy with 57 (80%) having a negative biopsy. A nadir PSA level of <0.5 ng/ml was achieved in 43 of 71 patients (61%). The nadir level was obtained within 3 mo. At the last follow-up, 44% of the patients had no evidence of any disease progression. Whether or not these results are durable awaits further follow-up, but these short-term oncologic outcomes seem inferior to SP. Experience with salvage brachytherapy is limited, but some successes have been reported in terms of biochemical control [9,12]. Longer-term outcomes with salvage cryotherapy have recently been reported. Ng et al assessed the efficacy of salvage cryotherapy in 187 patients with locally recurrent prostate cancer after radiotherapy [11]. Approximately 70% of these patients also received 3 mo of neoadjuvant ADT. The mean follow-up period was 39 mo. Biochemical recurrence was defined as nadir PSA level plus 2 ng/ml. Patients with precryotherapy PSA levels of <4 ng/ml had 5-yr and 8-yr biochemical recurrence-free survival rates of 56% and 37%, respectively. In contrast, patients with precryotherapy PSA levels of 10 ng/ml had 5-yr and 8-yr biochemically recurrence-free survival rates of only 1% and 7%, respectively. The fourquadrant positive biopsy rate after salvage cryotherapy was 17%. Serum PSA level immediately prior to salvage cryotherapy was a predictive factor for biochemical recurrence according to univariate and multivariate analyses. The investigators recommended that salvage cryotherapy should be performed when serum PSA level is still relatively low because the procedure may potentially be curative in these patients. We have to acknowledge that patient populations may be different among SP and the other miniinvasive salvage therapies (HIFU and cryotherapy) explaining the different oncologic outcomes between these series. The eligibility criteria for SP in our study are very strict and included a lifeexpectancy >10 yr versus 5 yr in the study of Ng et al [11] with salvage cryotherapy. Patients with a life expectancy <10 yr may be less suitable for SP and other minimally invasive procedures such as salvage cryotherapy or HIFU may be more appropriate. Similarly, the median age in the Ng et al study was 70.9 yr (oldest patient, 81 yr) versus 65 yr (range: 61 69) in our current study. The mean PSA level in the largest study of salvage HIFU was 20.4 ng/ml, and the mean PSA level was 5.1 ng/ml in our study [16]. The overall outcomes have favored SP solely based on patient selection; however, as with the cryotherapy study, those with the lowest PSA levels still had an improved oncologic outcome with SP. We have to consider that there are several modalities to treat a local recurrence after radiation failure, but patients with few comorbidities and a life expectancy >10 yr are most appropriate for a SP. Our results demonstrate that SP is an effective oncologic procedure in terms of biochemical and clinical results. Because the presalvage PSA and biopsy Gleason grade markedly affect outcome, methods to better identify patients with radiationrecurrent prostate cancer earlier in the course of their disease are paramount. Although SP has been effective with respect to biochemical results, we cannot be certain that these results would translate into a reduced rate of disease-specific death. For example, those who remained free from recurrence tended have biopsy Gleason 7; from these data we cannot ascertain whether these patients were spared prostate-specific death as a result of SP. An additional benefit of retropubic SP is the staging information and potential therapeutic benefit obtained from the pelvic lymph node dissection. Several studies have assessed the morbidity of local recurrence after radiation failure for prostate cancer [17,18]. Holzman et al examined 121 patients who experienced clinical failure after radiation therapy [17]. With a mean follow-up period of 8.1 yr, 64 patients (53%) developed a symptomatic local recurrence. The most common patterns of recurrence were bladder-outlet obstruction requiring transurethral resection of the prostate (TURP; 44 patients) and hydronephrosis (24 patients) requiring urinary diversion with a ureteral stent or
6 european urology 55 (2009) nephrostomy tube. Clearly, failure to control the local cancer resulted in a significant risk for patients with local recurrence after radiation therapy. The reported positive biopsy rates after both HIFU and cryotherapy are thus quite concerning. Whether they will translate into symptomatic local failure requires further follow-up, but the <1% clinical local failure rate after SP is clear evidence as to the oncologic benefit of this procedure. While SP has demonstrated excellent oncologic outcomes, its widespread use has been limited because of the technical demands of the procedure as well as concerns regarding post-sp bladder-neck contracture and urinary incontinence [6]. Fortunately, intraoperative complications have decreased with increasing experience with this procedure. Most SPs are now performed via a standard retropubic approach using techniques similar to those employed for standard radical prostatectomy. Limited data is available on the perineal approach [19]. The risks of rectal injury, ureteral transection, and blood transfusion are similar to standard RP in experienced hands. This is likely related not only to improved surgical techniques but also to better targeted radiation therapy thus reducing the amount of periprostatic fibrosis. Urinary incontinence and bladder neck contracture, however, continue to be problematic. Incontinence after SP occurs in about 40% of patients with up to 25% of patients requiring an artificial urinary sphincter [6]. Concerns regarding urinary incontinence after SP have been one of the primary factors prompting investigation of less invasive salvage therapies. While HIFU, brachytherapy, and cryotherapy are considered less morbid than SP, these therapies are certainly not risk-free. Ng et al report acute urinary retention in 21% of patients, persistent lower urinary tract symptoms in 10% of patients, chronic pelvic pain in 14% of patients, and incontinence in 40% of patients after salvage cryotherapy [11]. One must also remember that, although salvage therapies using HIFU, brachytherapy, or cryotherapy may be associated with fewer postprocedure complications than SP, any salvage technique is first and foremost performed for oncologic reasons. These techniques should be shown to have similar oncologic outcomes for SP before they are considered as standards of care. This study has some limitations. This is a retrospective study over a long period ( ). Irradiation and surgical techniques obviously change over a long period. The last patients of the series have a short follow-up, so it is possible that we have underestimated some BCR. SP in our institution has been performed on a very select population (described in the methods section) by mainly two experienced surgeons. 5. Conclusions Salvage radical prostatectomy is an effective treatment for patients with local failure after radiation therapy. SP provides excellent local cancer control with only one patient in our series experiencing a clinical local recurrence, leading to 5-yr recurrence rates of approximately 45% for patients with biopsy Gleason 7. The effect of SP on prostate-specific mortality remains unclear. Author contributions: James A. Eastham had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Eastham, Paparel. Acquisition of data: Paparel. Analysis and interpretation of data: Cronin, Savage. Drafting of the manuscript: Eastham, Paparel, Scardino. Critical revision of the manuscript for important intellectual content: Eastham, Paparel. Statistical analysis: Cronin, Savage. Obtaining funding: Paparel. Administrative, technical, or material support: Eastham, Scardino, Paparel. Supervision: Eastham, Scardino. Other (specify): None. Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Funding/Support and role of the sponsor: None. References [1] Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294: [2] Zelefsky MJ, Fuks Z, Hunt M, et al. High dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53: [3] Bianco Jr FJ, Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Easthman JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:
7 410 european urology 55 (2009) [4] Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H. Deoxyribonucleic acid ploidy and serum prostate-specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999;161: [5] Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005;173: [6] Stephenson AJ, Scardino PT, Bianco Jr FJ, Diblasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004;172: [7] Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1998;16: [8] Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999;94: [9] Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999;54: [10] Izawa JI, Madsen LT, Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002;20: [11] Ng CK, Moussa M, Downey DB, et al. Salvage cryoablation of the prostate: follow-up and analysis of predictive factors for outcome. J Urol 2007;178: [12] Ghafar MA, Johnson CW, De La Taille A, et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001;166: [13] Allen GW, Howard AR, Jarrard DF, et al. Management of prostate cancer recurrences after radiation therapy brachytherapy as a salvage option. Cancer 2007;110: [14] Ismail M, Ahmed S, Kastner C, et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100: [15] Ahmed S, Lindsey B, Davies J. Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy. Prostate Cancer Prostatic Dis 2005;8:31 5. [16] Gelet A, Chapelon JY, Poissonnier L, et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004;63: [17] Holzman M, Carlton Jr CE, Scardino PT. The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J Urol 1991;146: [18] Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005;23: [19] van der Poel HG, Beetsma DB, van Boven H, Horenblas S. Perineal salvage prostatectomy for radiation resistant prostate cancer. Eur Urol 2007;51: Editorial Comment on: Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy Markus Graefen University Medical Center Eppendorf, Hamburg, Germany graefen@uke.uni-hamburg.de In this noteworthy study written by some of the most recognized experts in the field of radical prostatectomy (RP), two important messages are clear: first, salvage prostatectomy is at the edge of becoming an established therapeutic option for men with recurrent disease after any kind of radiation therapy [1]. Second, however, this procedure definitely belongs in the hands of experienced surgeons, as even with these practitioners the morbidity rate is not comparable to that of primary radical prostatectomy [2,3]. The growing experience with and fine tuning of radical prostatectomy means that today, patients can expect adequate functional results even after salvage RP. Besides continuous improvements of the surgical technique, this is a result of better targeted radiation therapy leading to less periprostatic fibrosis. Nevertheless, even in experienced hands, functional outcomes such as urinary continence are impacted by prior radiation therapy, and patients need to be aware of this. Salvage prostatectomy offers excellent local control, with only one patient with evidence of recurrence in this study; however, despite strict patient and tumour selection criteria (median PSA 5.1 ng/ml), almost half of the patients recurred after 5 yr [1]. Considering the fact that we will not know for some time if salvage RP will lead to an overall survival benefit, we need to find better selection criteria in order to identify patients who will benefit from such a precarious procedure. The current selection criteria, such as presalvage PSA, are controversial and obviously not sufficient. Van der Poel recently showed that PSA doubling time is an important predictor of outcome in this situation, which was not confirmed by the current study. Using the biopsy Gleason sum is suggested by the authors; however, we all know about the potential differences between biopsy Gleason grade and final pathologic Gleason grade [4].
8 european urology 55 (2009) Even though it sounds like an editorial comment cliché, better markers and imaging techniques are needed to improve the identification of patients who are ideal candidates for such a procedure those with an adequate life expectancy and nonmetastasized disease. References [1] Paparel P, Cronin AM, Savage C, Scardino PT, Eastham JA. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur Urol 2009;55: [2] Graefen M, Walz J, Huland H. Open retropubic nervesparing radical prostatectomy. Eur Urol 2006;49: [3] van der Poel HG, Beetsma DB, van Boven H, Horenblas S. Perineal salvage prostatectomy for radiation-resistant prostate cancer. Eur Urol 2007;51: [4] Chun FK-H, Steuber T, Erbersdobler A, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49: DOI: /j.eururo DOI of original article: /j.eururo
PSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationSalvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration
EUROPEAN UROLOGY 60 (2011) 205 210 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Markus Graefen on pp. 211 213 of this issue
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationDisease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate Cancer
EUROPEAN UROLOGY 60 (2011) 405 410 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by J. Stephen Jones on pp. 411 412 of this issue
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationDepartment of Urology, Cochin hospital Paris Descartes University
Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationOutcomes of salvage radical prostatectomy following more than one failed local therapy
Original Article - Urological Oncology https://doi.org/10.4111/icu.2018.59.3.152 pissn 2466-0493 eissn 2466-054X Outcomes of salvage radical prostatectomy following more than one failed local therapy Arjun
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationHow to deal with patients who fail intracavitary treatment
How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationRadiation therapy for localized prostate cancer is a main form of therapy
MANAGEMENT OF RADIATION FAILURE IN PROSTATE CANCER Selection of Salvage Cryotherapy Patients Aaron E. Katz, MD, Mohamed A. Ghafar, MD Department of Urology, College of Physicians & Surgeons of Columbia
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationS Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationTreatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience
Treatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience Scott Quarrier, 1 Aaron Katz, 2 Jonathan Haas 3 Abstract
More informationda Vinci Prostatectomy
da Vinci Prostatectomy Justin T. Lee MD Director of Robotic Surgery Urology Associates of North Texas (UANT) USMD Prostate Cancer Center (www.usmdpcc.com) Prostate Cancer Facts Prostate cancer Leading
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More information1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:
ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationOncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting
END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationEffective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18
PROVIDENCE HEALTH PLANS MEDICAL (HIFU) (All Lines of Business Except Medicare) Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 11/1/18 Medical Officer
More informationThe Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy
european urology 51 (2007) 940 948 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Natural History of Noncastrate Metastatic Prostate Cancer after Radical
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationCytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer
Cytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer Timothy G. Wilson, MD Professor and Chair of Urology John Wayne Cancer Institute Santa Monica, California Disclosures I am on
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationComparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer
Original research Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer Khurram M. Siddiqui, MBBS, MSc, FRCS, FEBU; * Michele Billia, MD; * Andrew Williams,
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationRADICAL PROSTATECTOMY IS SElected
ORIGINAL CONTRIBUTION Adjuvant for Pathologically Advanced Prostate Cancer A Randomized Clinical Trial Ian M. Thompson, Jr, MD Catherine M. Tangen, DrPH Jorge Paradelo, MD M. Scott Lucia, MD Gary Miller,
More informationJaspreet S. Sandhu,*,, Geoffrey T. Gotto,*, Luis A. Herran, Peter T. Scardino, James A. Eastham and Farhang Rabbani
Age, Obesity, Medical Comorbidities and Surgical Technique are Predictive of Symptomatic Anastomotic Strictures After Contemporary Radical Prostatectomy Jaspreet S. Sandhu,*,, Geoffrey T. Gotto,*, Luis
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationSalvage Cryotherapy. Bernard Malavaud MD, PhD, FEBU Institut Universitaire du Cancer Toulouse (France)
Urethra protection Argon decompression -40 /-60 C 17G hollow needles Salvage Cryotherapy Ice all TRUS positioning & monitoring temperature monitoring of the rectal wall ernard Malavaud MD, PhD, FEU Institut
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationZonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy
european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical
More informationOutcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing Radical Prostatectomy
european urology 52 (2007) 1058 1066 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationSalvage Brachytherapy After External-Beam Irradiation for Prostate Cancer
Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Review Article [1] February 01, 2004 By David C. Beyer, MD [2] The options available for patients with recurrent prostate cancer
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationGood Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic Prostatectomy
european urology 54 (2008) 344 352 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Good Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More information